Baird Notes Encouraging Alexion Pharmaceuticals (ALXN) ALXN1210 Update at ASH

Baird analyst Michael Ulz noted an encouraging interim update with Phase 3 recruiting data from Alexion Pharmaceuticals (NASDAQ: ALXN) at ASH.

Ulz commented, "At the American Society of Hematology meeting (ASH), updated Phase 1/2 data for ALXN1210, dosed monthly, in PNH patients, were provided. As previously indicated, rapid, complete and sustained inhibition of complement was achieved with the most notable updates related to LDH levels. Overall, the updated data are encouraging and supportive of continued development. Indeed, recruitment in the pivotal program for ALXN1210 has already begun."

The firm maintained a Neutral rating and price target of $145 on ALXN.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $122.96 yesterday.

You May Also Be Interested In

• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
• Inflation surprise puts AUD in good position - ING
• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'